Literature DB >> 27811149

Eph Receptor Tyrosine Kinases in Tumor Immunity.

Eileen Shiuan1,2, Jin Chen3,4,5,6,7.   

Abstract

The family of Eph receptor tyrosine kinases and their ephrin ligands regulate a diverse array of physiologic processes, such as axonal guidance, bone remodeling, and immune cell development and trafficking. Eph/ephrin interactions have also been implicated in various pathologic processes, including inflammation, cancer, and tumor angiogenesis. Because Eph receptors play prominent roles in both the immune system and cancer, they likely impact the tumor immune microenvironment, an area in which Eph receptors remain understudied. Here, we provide the first comprehensive review of Eph receptors in the context of tumor immunity. With the recent rise of cancer immunotherapies as promising therapeutic interventions, further elucidation of the roles of Eph receptors in the tumor immune microenvironment will be critical for understanding and developing novel targets against tumor immune evasion. Cancer Res; 76(22); 6452-7. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27811149      PMCID: PMC5290221          DOI: 10.1158/0008-5472.CAN-16-1521

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  EphB6 crosslinking results in costimulation of T cells.

Authors:  Hongyu Luo; Guang Yu; Yulian Wu; Jiangping Wu
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 2.  Mechanisms of ephrin-Eph signalling in development, physiology and disease.

Authors:  Artur Kania; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-21       Impact factor: 94.444

Review 3.  Recent advances on T-cell regulation by receptor tyrosine kinases.

Authors:  Jiangping Wu; Hongyu Luo
Journal:  Curr Opin Hematol       Date:  2005-07       Impact factor: 3.284

4.  Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment.

Authors:  Thomas Korff; Jennifer Braun; Dennis Pfaff; Hellmut G Augustin; Markus Hecker
Journal:  Blood       Date:  2008-04-29       Impact factor: 22.113

5.  Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Authors:  Hideho Okada; Lisa H Butterfield; Ronald L Hamilton; Aki Hoji; Masashi Sakaki; Brian J Ahn; Gary Kohanbash; Jan Drappatz; Johnathan Engh; Nduka Amankulor; Mark O Lively; Michael D Chan; Andres M Salazar; Edward G Shaw; Douglas M Potter; Frank S Lieberman
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

6.  Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice.

Authors:  Tatsuma Okazaki; Amy Ni; Peter Baluk; Oluwasheyi A Ayeni; Jennifer Kearley; Anthony J Coyle; Alison Humbles; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

7.  Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity.

Authors:  Shinjiro Yamaguchi; Tomohide Tatsumi; Tetsuo Takehara; Akira Sasakawa; Hayato Hikita; Keisuke Kohga; Akio Uemura; Ryotaro Sakamori; Kazuyoshi Ohkawa; Norio Hayashi
Journal:  Cancer Immunol Immunother       Date:  2008-04-26       Impact factor: 6.968

8.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

9.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.

Authors:  Tomohide Tatsumi; Christopher J Herrem; Walter C Olson; James H Finke; Ronald M Bukowski; Michael S Kinch; Elena Ranieri; Walter J Storkus
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Authors:  Manabu Hatano; Naruo Kuwashima; Tomohide Tatsumi; Jill E Dusak; Fumihiko Nishimura; Karlyne M Reilly; Walter J Storkus; Hideho Okada
Journal:  J Transl Med       Date:  2004-11-24       Impact factor: 5.531

View more
  23 in total

Review 1.  Microenvironmental Metabolism Regulates Antitumor Immunity.

Authors:  Verra M Ngwa; Deanna N Edwards; Mary Philip; Jin Chen
Journal:  Cancer Res       Date:  2019-07-30       Impact factor: 12.701

2.  Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.

Authors:  Wen-Hao Yang; Jong-Ho Cha; Weiya Xia; Heng-Huan Lee; Li-Chuan Chan; Ying-Nai Wang; Jennifer L Hsu; Guoxin Ren; Mien-Chie Hung
Journal:  Cancer Res       Date:  2018-05-22       Impact factor: 12.701

3.  Molecular Profiling of Exceptional Responders to Cancer Therapy.

Authors:  Marijo Bilusic; Daniel Girardi; Yan Zhou; Kyungsuk Jung; Jianming Pei; Michael Slifker; Qingrong Chen; Daoud Meerzaman; Katherine Alpaugh; Denise Young; Douglas Flieder; Phillip Gray; Elizabeth Plimack
Journal:  Oncologist       Date:  2020-11-28

4.  EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.

Authors:  Silvia Garcia-Monclús; Roser López-Alemany; Olga Almacellas-Rabaiget; David Herrero-Martín; Juan Huertas-Martinez; Laura Lagares-Tena; Piedad Alba-Pavón; Lourdes Hontecillas-Prieto; Jaume Mora; Enrique de Álava; Santi Rello-Varona; Paloma H Giangrande; Oscar M Tirado
Journal:  Int J Cancer       Date:  2018-04-16       Impact factor: 7.396

5.  EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling.

Authors:  Shinya Sato; Suhas Vasaikar; Adel Eskaros; Young Kim; James S Lewis; Bing Zhang; Andries Zijlstra; Alissa M Weaver
Journal:  JCI Insight       Date:  2019-12-05

6.  Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies.

Authors:  Sanjoy Das; Bireswar Bhattacharya; Biplajit Das; Bibek Sinha; Taison Jamatia; Kishan Paul
Journal:  Indian J Surg Oncol       Date:  2019-08-19

7.  Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer.

Authors:  Seong Hye Park; Min Jee Jo; Bo Ram Kim; Yoon A Jeong; Yoo Jin Na; Jung Lim Kim; Soyeon Jeong; Hye Kyeong Yun; Dae Yeong Kim; Bu Gyeom Kim; Sang Hee Kang; Sang Cheul Oh; Dae-Hee Lee
Journal:  Theranostics       Date:  2019-04-12       Impact factor: 11.556

8.  EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.

Authors:  Weimei Huang; Anqi Lin; Peng Luo; Yuchen Liu; Wentao Xu; Weiliang Zhu; Ting Wei; Qingwen Lyu; Linlang Guo; Jian Zhang
Journal:  Cancer Gene Ther       Date:  2020-08-06       Impact factor: 5.987

9.  EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells.

Authors:  Patrice N Mimche; Choon M Lee; Sylvie M Mimche; Manoj Thapa; Arash Grakoui; Mark Henkemeyer; Tracey J Lamb
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

10.  MicroRNA-302b negatively regulates IL-1β production in response to MSU crystals by targeting IRAK4 and EphA2.

Authors:  Teng Ma; Xiao Liu; Zhifu Cen; Chuan Xin; Mingfeng Guo; Chaoyu Zou; Wenpeng Song; Rou Xie; Kailun Wang; Hong Zhou; Jun Zhang; Zhen Wang; Ce Bian; Kaijun Cui; Jiong Li; Yu-Quan Wei; Jing Li; Xikun Zhou
Journal:  Arthritis Res Ther       Date:  2018-02-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.